Antibody Drugs in Alzheimer’s Disease

Jinghan Zhou

doi:10.62051/0p4fdx33

Authors

Jinghan Zhou

DOI:

https://doi.org/10.62051/0p4fdx33

Keywords:

Alzheimer's disease; immunotherapy; Aducanumab; Lecanemab; CCTM2.

Abstract

Alzheimer's disease is one of the important causes of Alzheimer's disease. The prevalence rate has been increasing in recent years, which is a hot issue for the medical community. In view of the pathogenesis of Alzheimer's disease is still not exactly diagnosed, the research and development of related drugs is not particularly ideal. Existing drugs mostly stay in symptomatic treatment. However, in recent years, the medical community has gradually turned to causative treatment. Among them, disease-modifying therapy (DMT) is the most frequently studied drug at present, accounting for 82.5% of the total drugs under consideration. Among the DMT-class drugs, 16 (equivalent to 15.4%) are specifically designed as anti-amyloid beta (Aβ) monoclonal antibodies (Mabs), while 11 (accounting for 10.6%) target tau proteins with monoclonal antibody technology. Through reviewing past literature and comparing data, this paper takes Aducanumab, Lecanemab, and CCTM2 as examples to explore the therapeutic principles and make a summary.

Downloads

Download data is not yet available.

References

[1] A. Atri, The Alzheimer's disease clinical spectrum: diagnosis and management, Med. Clin. North. Am. 103(2019)263–293.

[2] V.L. Villemagne, S. Burnham, P. Bourgeat, et al. Amyloid ß deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study, Lancet Neurol. 12(2013)357-367.

[3] Information on: http://wonder.cdc.gov/mcd-icd10-privisional.html

[4] C.R. Jr. Jack, D.S. Knopman, W.J. Jagust, R.C. Petersen, M.W. Weiner, P.S. Aisen, L.M. Shaw, P. Vemuri, H.J. Wiste, S.D. Weigand, T.G. Lesnick, V.S. Pankratz, M.C. Donohue, J.Q. Trojanowski, Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers, Lancet Neurol. 12(2013)207-16.

[5] W.D. Brenowitz, R.A. Hubbard, C.D. Keene, et al. Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample, Alzheimer's Dement. 13(2017)654-662.

[6] B.A. Gordon, T.M. Blazey, Y. Su, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: A longitudinal study, Lancet Neurol.;17(2018)241-250.

[7] Y.T. Quiroz, H. Zetterberg, E.M. Reiman, et al. Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: A cross-sectional and longitudinal cohort study, Lancet Neuro.19(2020)513-521.

[8] N. Barthelemy, N. Joseph-Mathurin, B.A. Gordon, et al. A soluble phosphorylated tau signature links tau, amyloid, and the evolution of stages of dominantly inherited Alzheimer's disease, Nat. Med. 26(2020)398-407.

[9] R.A. Sperling, P.S. Aisen, L.A. Beckett, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's Dement. 7(2011)280-292.

[10] M.S. Albert, S.T. DeKosky, D. Dickson, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's Dement. 7(2011)270-279.

[11] G.M. McKhann, D.S. Knopman, H. Chertkow, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's Dement. 7(2011)263-269.

[12] Information on: https://www.who.int/news-room/fact-sheets/detail/dementia

[13] Information on: http://www.alz.co.uk/research/world-report-2018.

[14] S. Silvestro, A. Valeri, E. Mazzon, Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis? Int. J. Mol. Sci. 23(2022)2011.

[15] E. Karran, M. Mercken, B. De Strooper, The amyloid cascade hypothesis for Alzheimer’s disease: An appraisal for the development of therapeutics, Nat. Rev. Drug. Discov.10(2011) 698–712.

[16] D.J. Selkoe, J. Hardy, The amyloid hypothesis of Alzheimer’s disease at 25 years, EMBO. Mol. Med. 8(2016) 595–608.

[17] V.L. Villemagne, K.A. Perez, K.E. Pike, W.M. Kok, C.C. Rowe, A.R. White, P. Bourgeat, O. Salvado, J. Bedo, C.A. Hutton, Blood-borne amyloid-β dimer correlates with clinical markers of Alzheimer’s disease, J. Neurosci. 30(2010)6315–6322.

[18] L. Montoliu-Gaya, S. Villegas, Aβ-Immunotherapeutic strategies: A wide range of approaches for Alzheimer’s disease treatment, Expert Rev. Mol. Med. 18(2016) e13.

[19] B. Winblad, N. Andreasen, L. Minthon, A. Floesser, G. Imbert, T. Dumortier, R.P. Maguire, K. Blennow, J. Lundmark, M. Staufenbiel, et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer’s disease: Randomized, double-blind, placebo-controlled, first-in-human study, Lancet. Neurol. 11(2012) 597–604.

[20] C.A. Lemere, Immunotherapy for Alzheimer’s disease: Hoops and hurdles, Mol. Neurodegener. 8(2013)36.

[21] K. Suzuki, A. Iwata, T. Iwatsubo, The past, present, and future of disease-modifying therapies for Alzheimer’s disease, Proc. Jpn. Acad. Ser. B. 93(2017)757–771.

[22] E. Valera, B. Spencer, E. Masliah, Immunotherapeutic approaches targeting amyloid-β, α-synuclein, and tau for the treatment of neurodegenerative disorders, Neurotherapeutics. 13(2016)179–189.

[23] M. Abyadeh, V. Gupta, N. Chitranshi, Y. Wu, A. Amirkhani, A. Meyfour, S. Sheriff, T. Shen, K. Dhiman, et al. Comparative Analysis of Aducanumab, Zagotenemab, and Pioglitazone as Targeted Treatment Strategies for Alzheimer’s Disease, Aging Dis. 12(2021)1964–1976.

[24] J.W. Arndt, F. Qian, B.A. Smith, et al. The structural and kinetic basis for the selectivity of Aducanumab for aggregated forms of amyloid-β, Sci. Rep. 8(2018)1–16.

[25] J.W. Arndt, F. Qian, B.A. Smith, C. Quan, K.P. Kilambi, M.W. Bush, T. Walz, R.B. Pepinsky, T. Bussière, S. Hamann, T.O. Cameron, P.H. Weinreb, Structural and kinetic basis for the selectivity of Aducanumab for aggregated forms of amyloid-β, Sci. Rep. 8(2018)6412.

[26] Information on: https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval

[27] L. Soderberg, M. Johannesson, P. Nygren, H. Laudon, F. Eriksson, G. Osswald, et al. Lecanemab, Aducanumab, and gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer’s disease, Neurotherapeutics.20(2023)195-206.

[28] S. Tucker, C. Möller, K. Tegerstedt, A. Lord, H. Laudon, J. Sjödahl, L. Söderberg, E. Spens, C. Sahlin, E.R. Waara, A. Satlin, P. Gellerfors, G. Osswald, L. Lannfelt, the murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice, J. Alzheimers Dis. 43(2015)575-88.

[29] C.H. Dyck, C.J. Swanson, P. Aisen, R.J. Bateman, C. Chen, M. Gee, M. Kanekiyo, D. Li, L. Reyderman, S. Cohen, L. Froelich, S. Katayama, M. Sabbagh, B. Vellas, D. Watson, S. Dhadda, M. Irizarry, L.D. Kramer, T. Iwatsubo, Lecanemab in Early Alzheimer's Disease, N. Engl. J. Med. 388(2023)9-21.

[30] J. Cummings, L. Apostolova, G.D. Rabinovici, A. Atri, P. Aisen, S. Greenberg, S. Hendrix, D. Selkoe, M. Weiner, R.C. Petersen, S. Salloway, Lecanemab: Appropriate Use Recommendations, J. Prev. Alzheimers Dis.10(2023)362-377.

[31] S. C. Neu, J. Pa, W. Kukull, D. Beekly, A. Kuzma, P. Gangadharan, et al, Apolipoprotein E genotype and sex risk factors for Alzheimer’ s disease: a meta-analysis, JAMA Neurol. 74(2017) 1178–1189.

[32] S. Gaikwad, N. Puangmalai, M. Sonawane, M. Montalbano, R. Price, M.S. Iyer, A. Ray, S. Moreno R. Kayed, Nasal tau immunotherapy clears intracellular tau pathology and improves cognitive functions in aged tauopathy mice, Sci. Transl. Med. 16(2024) eadj5958.

[33] L.A. Sandusky-Beltran, E.M. Sigurdsson. Tau immunotherapies: Lessons learned, current status and future considerations. Neuropharmacology. 175(2020)108-104.

[34] J.K. Holth, et al. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans, Science. 363(2019) 880–884.